Your browser doesn't support javascript.
loading
The Putative S1PR1 Modulator ACT-209905 Impairs Growth and Migration of Glioblastoma Cells In Vitro.
Bien-Möller, Sandra; Chen, Fan; Xiao, Yong; Köppe, Hanjo; Jedlitschky, Gabriele; Meyer, Ulrike; Tolksdorf, Céline; Grube, Markus; Marx, Sascha; Tzvetkov, Mladen V; Schroeder, Henry W S; Rauch, Bernhard H.
Afiliación
  • Bien-Möller S; Department of General Pharmacology, University Medicine Greifswald, 17475 Greifswald, Germany.
  • Chen F; Department of Neurosurgery, University Medicine Greifswald, 17475 Greifswald, Germany.
  • Xiao Y; Department of General Pharmacology, University Medicine Greifswald, 17475 Greifswald, Germany.
  • Köppe H; Department of Neurosurgery, University Medicine Greifswald, 17475 Greifswald, Germany.
  • Jedlitschky G; Department of General Pharmacology, University Medicine Greifswald, 17475 Greifswald, Germany.
  • Meyer U; Department of Neurosurgery, University Medicine Greifswald, 17475 Greifswald, Germany.
  • Tolksdorf C; Department of General Pharmacology, University Medicine Greifswald, 17475 Greifswald, Germany.
  • Grube M; Department of Neurosurgery, University Medicine Greifswald, 17475 Greifswald, Germany.
  • Marx S; Department of General Pharmacology, University Medicine Greifswald, 17475 Greifswald, Germany.
  • Tzvetkov MV; Division of Pharmacology and Toxicology, School of Medicine and Health Sciences, Carl von Ossietzky, Universität Oldenburg, 26129 Oldenburg, Germany.
  • Schroeder HWS; Division of Pharmacology and Toxicology, School of Medicine and Health Sciences, Carl von Ossietzky, Universität Oldenburg, 26129 Oldenburg, Germany.
  • Rauch BH; Department of General Pharmacology, University Medicine Greifswald, 17475 Greifswald, Germany.
Cancers (Basel) ; 15(17)2023 Aug 26.
Article en En | MEDLINE | ID: mdl-37686550
ABSTRACT
Glioblastoma (GBM) is still a deadly tumor due to its highly infiltrative growth behavior and its resistance to therapy. Evidence is accumulating that sphingosine-1-phosphate (S1P) acts as an important tumor-promoting molecule that is involved in the activation of the S1P receptor subtype 1 (S1PR1). Therefore, we investigated the effect of ACT-209905 (a putative S1PR1 modulator) on the growth of human (primary cells, LN-18) and murine (GL261) GBM cells. The viability and migration of GBM cells were both reduced by ACT-209905. Furthermore, co-culture with monocytic THP-1 cells or conditioned medium enhanced the viability and migration of GBM cells, suggesting that THP-1 cells secrete factors which stimulate GBM cell growth. ACT-209905 inhibited the THP-1-induced enhancement of GBM cell growth and migration. Immunoblot analyses showed that ACT-209905 reduced the activation of growth-promoting kinases (p38, AKT1 and ERK1/2), whereas THP-1 cells and conditioned medium caused an activation of these kinases. In addition, ACT-209905 diminished the surface expression of pro-migratory molecules and reduced CD62P-positive GBM cells. In contrast, THP-1 cells increased the ICAM-1 and P-Selectin content of GBM cells which was reversed by ACT-209905. In conclusion, our study suggests the role of S1PR1 signaling in the growth of GBM cells and gives a partial explanation for the pro-tumorigenic effects that macrophages might have on GBM cells.
Palabras clave

Texto completo: 1 Banco de datos: MEDLINE Idioma: En Revista: Cancers (Basel) Año: 2023 Tipo del documento: Article País de afiliación: Alemania

Texto completo: 1 Banco de datos: MEDLINE Idioma: En Revista: Cancers (Basel) Año: 2023 Tipo del documento: Article País de afiliación: Alemania